Takeda reported that zasocitinib, a TYK2 inhibitor acquired in a prior deal, met co‑primary and key secondary endpoints in two Phase 3 trials for plaque psoriasis. The company said more than half of treated patients achieved clear or almost clear skin and plans regulatory submissions in 2026. Safety data disclosed common adverse events—respiratory infections, upper‑respiratory symptoms and acne—without detailing serious signal rates. Takeda highlighted forthcoming detailed results at medical meetings and broader development across inflammatory indications, including head‑to‑head studies versus competitors. The win underscores continued interest in selective oral TYK2 inhibitors as potential oral alternatives to injectable biologics and positions Takeda to compete in a fast‑moving dermatology market.